

IFW

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/689,225
	Filing Date	October 20, 2003
	First Named Inventor	GH Cantor
	Art Unit	not yet assigned
	Examiner Name	not yet assigned
Total Number of Pages in This Submission	Attorney Docket Number	01274.US1

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Executed Declaration Return Receipt Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Pharmacia & Upjohn Company Edward F. Rehberg, 34,703
Signature	<i>Edward F. Rehberg</i>
Date	8-03-04

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Valerie L. Schipper		
Signature	<i>Valerie L. Schipper</i>	Date	3 rd Aug-2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$)**0.00**

Complete if Known

Application Number	10/689,225
Filing Date	October 20, 2003
First Named Inventor	GH Cantor
Examiner Name	not yet assigned
Art Unit	not yet assigned
Attorney Docket No.	01274.US1

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit
Account
Number
Deposit
Account
Name

21-0718

Pharmacia & Upjohn Company

The Director is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1)					(\$) 0.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims	Fee from below	Fee Paid
Total Claims		-20** = 0	X \$0.00	= \$0.00
Independent Claims		-3** = 0	X \$0.00	= \$0.00
Multiple Dependent			\$0.00	= \$0.00

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)**0.00**

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)**0.00**

SUBMITTED BY

Name (Print/Type) **Edward F. Rehberg**

Registration No. **34,703**
(Attorney/Agent)

(Complete if applicable)

Telephone **(269) 833-7829**

Signature

Date

8-03-04

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT/Docket No.: 01274.US1

DECLARATION (37 CFR §1.63) AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **METHOD OF USING ANIMAL MODELS TO PREDICT ADVERSE DRUG REACTIONS**, Docket No. 01274.US1, the specification of which

- ☐ is attached hereto.
- ☒ was filed on October 20, 2003 as Application Serial No. 10/689,225.
- ☐ was filed on as PCT International Application No. and was amended under PCT Article 19 on , if applicable.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, ~~as amended by any amendment referred to above.~~ *GHC June 4, 2004*

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 CFR §1.56(a).

I hereby claim the benefit under 35 USC §119(e) of any United States provisional application(s) listed below:

Application Serial No.	Filing Date (Day/Month/Year)
---------------------------	---------------------------------

60/421,950	October 29, 2002
------------	------------------

I hereby claim foreign priority benefits under 35 USC §119(a)-(d), or §365(b), of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT International Application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT International Application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application on which priority is claimed:

Application Serial No.	Country	Filing Date (Day/Month/Year)	Priority Claimed (Yes/No)
---------------------------	---------	---------------------------------	------------------------------

I hereby claim the benefit under 35 USC §120, of any United States application(s) or PCT International Application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of 35 USC §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56(a), ~~which occurred between the filing date of the prior application and the national or PCT international filing date of this application:~~ **GHC June 4, 2004**

Application
Serial No.

Filing Date

Status (Patented,
Pending, Abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint

☒ the practitioners associated with Customer Number



25533

PATENT AND TRADEMARK OFFICE

☐ Thomas A. Wootton (Registration No. 35,004); Lucy X. Yang (Registration No. 40,259); Edward F. Rehberg (Registration No. 34,703); John H. Engelmann (Registration No. 28,075); Austin W. Zhang (Registration No. 48,061); Stephen L. Nesbitt (Registration No. 28,981); Mary J. Hosley (Registration No. 48,324); Jonathan P. O'Brien (Registration No. 50,852); and J. Trevor Lumb (Registration No. 28,567); all registered to practice before the Patent and Trademark Office.

as my attorneys or agents with full power of substitution and revocation to prosecute this application and all divisions and continuations thereof and to transact all business in the Patent and Trademark Office connected therewith and request that all correspondence and telephone communications be directed to the following person at the mailing address and telephone number hereafter given:

Name : Edward F. Rehberg, Attorney

Registration No. : 34,703


Address : Pharmacia & Upjohn Company
Global Intellectual Property
301 Henrietta Street
Kalamazoo, Michigan 49001

Telephone No. : (269) 833-7829 or (269) 833-9500

Telefax No. : (269) 833-8897 or (269) 833-2316

Inventor's Signature	<u>Glenn H. Cantor</u>	Date	<u>June 4, 2004</u>
Full name of sole or first inventor: Glenn H. Cantor			
Residence: Kalamazoo, Michigan 49008 ^{Hopewell Township, New Jersey 08540} Citizenship: USA			
Post Office Address: 4033 East Hillandale, Kalamazoo, Michigan 49008 77 Elm Ridge Road, Princeton, New Jersey 08540			

Inventor's Signature	Date
Full name of second joint inventor: Martin Geppert	
Residence: Glayhall, Ilford, Essex, United Kingdom IG5 OBG Citizenship: Germany	
Post Office Address: 33 Abbotswood Gardens, Glayhall, Ilford, Essex, United Kingdom IG5 OBG	

**DECLARATION (37 CFR §1.63) AND POWER OF ATTORNEY**

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **METHOD OF USING ANIMAL MODELS TO PREDICT ADVERSE DRUG REACTIONS**, Docket No. 01274.US1, the specification of which

- ☐ is attached hereto.
- ☒ was filed on October 20, 2003 as Application Serial No. 10/689,225.
- ☐ was filed on as PCT International Application No. and was amended under PCT Article 19 on , if applicable.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 CFR §1.56(a).

I hereby claim the benefit under 35 USC §119(e) of any United States provisional application(s) listed below:

<u>Application</u> <u>Serial No.</u>	<u>Filing Date</u> <u>(Day/Month/Year)</u>
---	---

60/421,950	October 29, 2002
------------	------------------

I hereby claim foreign priority benefits under 35 USC §119(a)-(d), or §365(b), of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT International Application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT International Application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application on which priority is claimed:

<u>Application</u> <u>Serial No.</u>	<u>Country</u>	<u>Filing Date</u> <u>(Day/Month/Year)</u>	<u>Priority Claimed</u> <u>(Yes/No)</u>
---	----------------	---	--

I hereby claim the benefit under 35 USC §120, of any United States application(s) or PCT International Application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of 35 USC §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56(a), which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application
Serial No.

Filing Date

Status (Patented,
Pending, Abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint

☒ the practitioners associated with Customer Number



25533

PATENT AND TRADEMARK OFFICE

☐ Thomas A. Wootton (Registration No. 35,004); Lucy X. Yang (Registration No. 40,259); Edward F. Rehberg (Registration No. 34,703); John H. Engelmann (Registration No. 28,075); Austin W. Zhang (Registration No. 48,061); Stephen L. Nesbitt (Registration No. 28,981); Mary J. Hosley (Registration No. 48,324); Jonathan P. O'Brien (Registration No. 50,852); and J. Trevor Lumb (Registration No. 28,567); all registered to practice before the Patent and Trademark Office.

as my attorneys or agents with full power of substitution and revocation to prosecute this application and all divisions and continuations thereof and to transact all business in the Patent and Trademark Office connected therewith and request that all correspondence and telephone communications be directed to the following person at the mailing address and telephone number hereafter given:

Name : Edward F. Rehberg, Attorney

Registration No. : 34,703

Address : Pharmacia & Upjohn Company
Global Intellectual Property
301 Henrietta Street
Kalamazoo, Michigan 49001

Telephone No. : (269) 833-7829 or (269) 833-9500

Telefax No. : (269) 833-8897 or (269) 833-2316

Inventor's Signature _____ Date _____

Full name of sole or first inventor: ~~Glenn H. Cantor~~

Residence: ~~Kalamazoo, Michigan 49008~~ Citizenship: ~~USA~~


Post Office Address: ~~4033 East Hillandale, Kalamazoo, Michigan 49008~~

Inventor's Signature Martin Geppert Date 27th Feb. 2004

Full name of second joint inventor: Martin Geppert

Residence: Glayhall, Ilford, Essex, United Kingdom IG5 OBG Citizenship: Germany

Post Office Address: 33 Abbotswood Gardens, Glayhall, Ilford, Essex, United Kingdom IG5 OBG



LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>	Atty. Docket No. 01274.US1		Serial No. 10/689,225	
	Applicant GH Cantor, M Geppert			
	Filing Date October 20, 2003		Group (not yet assigned)	

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	5,523,222	June 4, 1996	Page et. al.	435	172.3	Aug 5, 1994
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AJ							
	AK							
	AL							
	AM							
	AN							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AO	Brayton, C., M. Justice, and C. A. Montgomery. 2001. Evaluating mutant mice: Anatomic pathology. Veterinary Pathology 38:1-19
AP	Campbell, K.H.S., J. McWhir, W.A. Ritchie, & I. Wilmut, 1996. Sheep Cloned by Nuclear Transfer from a Cultured Cell Line, Nature 380: 64-66
AQ	Gavaghan, C. L., E. Holmes, E. Lenz, I. D. Wilson, and J. K. Nicholson. 2000. An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL10J and Alpk: ApfCD mouse. FEBS Letters 484:169-174
AR	Griebel, G., J. Simiand, R. Steinberg, M. Jung, D. Gully, P. Roger, M. Geslin, B. Scatton, J. P. Maffrand, and P. Soubrie. 2002. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. Journal of Pharmacology and Experimental Therapeutics 301:333-345

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		Atty. Docket No. 01274.US1	Serial No. 10/689,225
		Applicant GH Cantor, M Geppert	
		Filing Date October 20, 2003	Group (not yet assigned)
	AS	Houdebine, L.M.; Transgenic Animal Generation and Use, Harwood Academic Press, 1997	
	AT	Robertson, D. G., M. D. Reily, J. C. Lindon, E. Holmes, and J. K. Nicholson. 2002. Metabonomic technology as a tool for rapid throughput in vivo toxicity screening, p. 583-626. In J. P. Vanden Heuvel, G. H. Perdew, W. B. Mattes, and W. F. Greenlee (ed.), Comprehensive Toxicology, vol. 14. Elsevier, Amsterdam	
	AU	Robertson, D. G., E. M. Urda, M. A. Breider, and R. M. Gauthier. 1998. Evaluation of hepatic toxicity of seven-day repeated-dose glutathione-depleting regimens in rats. Toxicology Methods 8:233-244	
	AV	Sundberg, J.P., and D. Boggess. 2000. Systematic approach to evaluation of mouse mutations, 1 ed. CRC Press, Boca Raton, Florida.	
	AW	Tymms, M.J., and I. Kola. 2001. Gene Knockout Protocols. Humana Press, Totawa, New Jersey.	
	AX	Ward, J. M., J.F.Mahler, R.R. Maronpot, and J.P. Sundberg. 2000. Pathology of genetically engineered mice, 1 ed. Iowa State University Press, Ames, Iowa.	
	AY	Warren, T. K., K. A. Mitchell, and B. P. Lawrence. 2000. Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) suppresses the humoral and cell-mediated immune responses to influenza A virus without affecting cytolytic activity in the lung. Toxicological Sciences 56:114-123	
	AZ	Wilmut, I., A.E. Schnieke, J. McWhir, A.J. Kind, & K.H.S. Campbell, 1997. Viable Offspring Derived From Fetal and Adult Mammalian Cells. Nature, 385: 810-813	
Examiner		Date Considered	